118 related articles for article (PubMed ID: 16301668)
21. HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses.
Abdelwahab SF; Cocchi F; Bagley KC; Kamin-Lewis R; Gallo RC; DeVico A; Lewis GK
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15006-10. PubMed ID: 14657379
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein.
Challita-Eid PM; Klimatcheva E; Day BT; Evans T; Dreyer K; Rimel BJ; Rosenblatt JD; Planelles V
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1617-24. PubMed ID: 9870314
[TBL] [Abstract][Full Text] [Related]
23. Regulation of CC chemokine receptor 5 in hepatitis G virus infection.
Nattermann J; Nischalke HD; Kupfer B; Rockstroh J; Hess L; Sauerbruch T; Spengler U
AIDS; 2003 Jul; 17(10):1457-62. PubMed ID: 12824783
[TBL] [Abstract][Full Text] [Related]
24. Statins disrupt CCR5 and RANTES expression levels in CD4(+) T lymphocytes in vitro and preferentially decrease infection of R5 versus X4 HIV-1.
Nabatov AA; Pollakis G; Linnemann T; Paxton WA; de Baar MP
PLoS One; 2007 May; 2(5):e470. PubMed ID: 17520029
[TBL] [Abstract][Full Text] [Related]
25. Human immunodeficiency virus type 1 infection of antigen-specific CD4 cytotoxic T lymphocytes.
Robbins PA; Roderiquez GL; Peden KW; Norcross MA
AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1397-406. PubMed ID: 9824317
[TBL] [Abstract][Full Text] [Related]
26. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
27. CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy.
Giovannetti A; Ensoli F; Mazzetta F; De Cristofaro M; Pierdominici M; Muratori DS; Fiorelli V; Aiuti F
Clin Exp Immunol; 1999 Oct; 118(1):87-94. PubMed ID: 10540164
[TBL] [Abstract][Full Text] [Related]
28. CD4 receptor-dependent entry of human immunodeficiency virus type-1 env-pseudotypes into CCR5-, CCR3-, and CXCR4-expressing human alveolar macrophages is preferentially mediated by the CCR5 coreceptor.
Park IW; Koziel H; Hatch W; Li X; Du B; Groopman JE
Am J Respir Cell Mol Biol; 1999 May; 20(5):864-71. PubMed ID: 10226056
[TBL] [Abstract][Full Text] [Related]
29. Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection.
Schroers R; Davis CM; Wagner HJ; Chen SY
Gene Ther; 2002 Jul; 9(13):889-97. PubMed ID: 12080383
[TBL] [Abstract][Full Text] [Related]
30. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.
Schols D; Proost P; Struyf S; Wuyts A; De Meester I; Scharpé S; Van Damme J; De Clercq E
Antiviral Res; 1998 Oct; 39(3):175-87. PubMed ID: 9833958
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of CCR5 expression by IL-12 through induction of beta-chemokines in human T lymphocytes.
Wang J; Guan E; Roderiquez G; Norcross MA
J Immunol; 1999 Dec; 163(11):5763-9. PubMed ID: 10570258
[TBL] [Abstract][Full Text] [Related]
32. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines.
Paxton WA; Liu R; Kang S; Wu L; Gingeras TR; Landau NR; Mackay CR; Koup RA
Virology; 1998 Apr; 244(1):66-73. PubMed ID: 9581779
[TBL] [Abstract][Full Text] [Related]
33. Endocytosis and recycling of the HIV coreceptor CCR5.
Signoret N; Pelchen-Matthews A; Mack M; Proudfoot AE; Marsh M
J Cell Biol; 2000 Dec; 151(6):1281-94. PubMed ID: 11121442
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.
Alkhatib G; Locati M; Kennedy PE; Murphy PM; Berger EA
Virology; 1997 Aug; 234(2):340-8. PubMed ID: 9268166
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.
Xiang J; George SL; Wünschmann S; Chang Q; Klinzman D; Stapleton JT
Lancet; 2004 Jun; 363(9426):2040-6. PubMed ID: 15207954
[TBL] [Abstract][Full Text] [Related]
36. A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors.
Blanpain C; Buser R; Power CA; Edgerton M; Buchanan C; Mack M; Simmons G; Clapham PR; Parmentier M; Proudfoot AE
J Leukoc Biol; 2001 Jun; 69(6):977-85. PubMed ID: 11404385
[TBL] [Abstract][Full Text] [Related]
37. Anti-HIV type 1 activity of wild-type and functional defective RANTES intrakine in primary human lymphocytes.
Yang AG; Zhang X; Torti F; Chen SY
Hum Gene Ther; 1998 Sep; 9(14):2005-18. PubMed ID: 9759928
[TBL] [Abstract][Full Text] [Related]
38. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains.
Alfano M; Schmidtmayerova H; Amella CA; Pushkarsky T; Bukrinsky M
J Exp Med; 1999 Sep; 190(5):597-605. PubMed ID: 10477545
[TBL] [Abstract][Full Text] [Related]
39. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
[TBL] [Abstract][Full Text] [Related]
40. Blockade of CC chemokine receptor 5 (CCR5)-tropic human immunodeficiency virus-1 replication in human lymphoid tissue by CC chemokines.
Margolis LB; Glushakova S; Grivel JC; Murphy PM
J Clin Invest; 1998 May; 101(9):1876-80. PubMed ID: 9576751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
